{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:56:47Z","timestamp":1790895407073,"version":"4.1.0"},"reference-count":110,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Liver Dis"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:p>Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are chronic cholestatic liver diseases that have undergone notable therapeutic advances in recent years. Recent advances in PBC have expanded treatment options beyond ursodeoxycholic acid, enabling earlier risk stratification and use of second-line therapies, allowing practitioners to personalize treatment. Meanwhile, multiple investigational agents are under evaluation in clinical trials for PSC, yet there remain no approved treatments. This review summarizes advances in epidemiology, diagnosis, and treatment of the underlying disease along with the extrahepatic manifestations associated with PBC and PSC. PBC has entered a treat-to-target era, while PSC remains without approved disease-modifying therapy despite a rapidly expanding trial pipeline.<\/jats:p>","DOI":"10.1055\/a-2952-2261","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T22:58:39Z","timestamp":1789513119000},"page":"103-115","source":"Crossref","is-referenced-by-count":0,"title":["Advances in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis"],"prefix":"10.1055","volume":"46","author":[{"given":"Sunny","family":"Sandhu","sequence":"additional","affiliation":[{"name":"Stanford University, California, United States","place":["Pleasanton"],"department":["Stanford Digestive Health, Division of Gastroenterology and Hepatology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9588-9364","authenticated-orcid":false,"given":"Aparna","family":"Goel","sequence":"additional","affiliation":[{"name":"Stanford University, California, United States","place":["Pleasanton"],"department":["Stanford Digestive Health, Division of Gastroenterology and Hepatology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"A Tanaka","year":"2024","journal-title":"Lancet"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"K D Lindor","year":"2019","journal-title":"Hepatology"},{"issue":"06","key":"ref3","doi-asserted-by":"crossref","first-page":"e0179","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology, prognosis, and treatment","volume":"7","author":"J Trivella","year":"2023","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"E J Carey","year":"2015","journal-title":"Lancet"},{"issue":"19","key":"ref6","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis","volume":"330","author":"R E Poupon","year":"1994","journal-title":"N Engl J Med"},{"issue":"02","key":"ref7","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","article-title":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","volume":"71","author":"M H Harms","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"ref8","first-page":"101168","article-title":"Loss of biochemical response at any time worsens outcomes in UDCA-treated patients with primary biliary cholangitis","volume":"6","author":"S B Roberts","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"06","key":"ref9","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"W J Lammers","year":"2014","journal-title":"Gastroenterology"},{"issue":"07","key":"ref10","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.14309\/ajg.0000000000000557","article-title":"Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase","volume":"115","author":"C F Murillo Perez","year":"2020","journal-title":"Am J Gastroenterol"},{"issue":"03","key":"ref11","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.cld.2018.03.007","article-title":"Natural history of primary biliary cholangitis in the ursodeoxycholic acid era: role of scoring systems","volume":"22","author":"A Goel","year":"2018","journal-title":"Clin Liver Dis"},{"issue":"01","key":"ref12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/HEP.0000000000000529","article-title":"Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: to what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?","volume":"79","author":"C Corpechot","year":"2024","journal-title":"Hepatology"},{"issue":"02","key":"ref13","doi-asserted-by":"crossref","first-page":"232","DOI":"10.14309\/ajg.0000000000002070","article-title":"Application of the latest advances in evidence-based medicine in primary biliary cholangitis","volume":"118","author":"K V Kowdley","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1111\/apt.70120","article-title":"Longitudinal relationship between elevated liver biochemical tests and negative clinical outcomes in primary biliary cholangitis: a population-based study","volume":"61","author":"K V Kowdley","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"ref15","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1016\/j.cgh.2024.06.035","article-title":"Dynamics of liver stiffness measurement and clinical course of primary biliary cholangitis","volume":"22","author":"L Lam","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"03","key":"ref16","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1001\/jama.2025.20067","article-title":"Primary biliary cholangitis","volume":"335","author":"M M Tana","year":"2026","journal-title":"JAMA"},{"issue":"10","key":"ref17","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1080\/13543784.2022.2130750","article-title":"Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC)","volume":"31","author":"A Wetten","year":"2022","journal-title":"Expert Opin Investig Drugs"},{"issue":"03","key":"ref18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clinre.2015.02.011","article-title":"Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: a meta-analysis","volume":"39","author":"A Y Grigorian","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"04","key":"ref19","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s10620-022-07704-4","article-title":"Efficacy and safety of bezafibrate alone or in combination with ursodeoxycholic acid in primary biliary cholangitis: systematic review and meta-analysis","volume":"68","author":"N S Khakoo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"23","key":"ref20","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"C Corpechot","year":"2018","journal-title":"N Engl J Med"},{"issue":"03","key":"ref21","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"A Tanaka","year":"2021","journal-title":"J Hepatol"},{"issue":"10","key":"ref22","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1111\/apt.70574","article-title":"Long-term use of fenofibrate as second-line therapy in primary biliary cholangitis: a retrospective study","volume":"63","author":"M Maxwell","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"issue":"09","key":"ref23","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.gastrohep.2023.01.001","article-title":"Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid","volume":"46","author":"D Ding","year":"2023","journal-title":"Gastroenterol Hepatol"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.14309\/ajg.0000000000002238","article-title":"Effectiveness of fenofibrate in treatment-naive patients with primary biliary cholangitis: a randomized clinical trial","volume":"118","author":"Y Liu","year":"2023","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref25","first-page":"39","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"J Lipscombe","year":"2001","journal-title":"Clin Nephrol"},{"issue":"06","key":"ref26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1111\/liv.14871","article-title":"Safety of fibrates in cholestatic liver diseases","volume":"41","author":"A F Carrion","year":"2021","journal-title":"Liver Int"},{"issue":"04","key":"ref27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1002\/hep.32117","article-title":"Primary biliary cholangitis: 2021 practice guidance update from the American Association for the Study of Liver Diseases","volume":"75","author":"K D Lindor","year":"2022","journal-title":"Hepatology"},{"issue":"09","key":"ref28","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"K V Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"09","key":"ref31","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"G M Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"02","key":"ref36","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"C L Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"12","key":"ref37","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1056\/NEJMra1506330","article-title":"Primary sclerosing cholangitis","volume":"375","author":"K N Lazaridis","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"ref38","doi-asserted-by":"crossref","first-page":"7817","DOI":"10.3390\/jcm14217817","article-title":"Gut-liver axis, microbiota, bile acids, and immune response in pathogenesis of primary sclerosing cholangitis: an overview","volume":"14","author":"F S Fousekis","year":"2025","journal-title":"J Clin Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0140-6736(25)02582-6","article-title":"Primary sclerosing cholangitis","volume":"407","author":"E von Seth","year":"2026","journal-title":"Lancet"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","article-title":"Primary sclerosing cholangitis","volume":"391","author":"J K Dyson","year":"2018","journal-title":"Lancet"},{"issue":"04","key":"ref41","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1053\/j.gastro.2008.01.042","article-title":"The natural history of small-duct primary sclerosing cholangitis","volume":"134","author":"E Bj\u00f6rnsson","year":"2008","journal-title":"Gastroenterology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4137\/CGast.S38451","article-title":"Primary sclerosing cholangitis: therapeutic options and surveillance management","volume":"9","author":"A Kumar","year":"2016","journal-title":"Clin Med Insights Gastroenterol"},{"issue":"07","key":"ref43","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/apt.16296","article-title":"Systematic review: non-invasive prognostic tests for primary sclerosing cholangitis","volume":"53","author":"A Mazhar","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1111\/apt.12979","article-title":"Reduction in alkaline phosphatase is associated with longer survival in primary sclerosing cholangitis, independent of dominant stenosis","volume":"40","author":"C Rupp","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"issue":"07","key":"ref45","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.cgh.2019.10.041","article-title":"Changes in liver stiffness, measured by magnetic resonance elastography, associated with hepatic decompensation in patients with primary sclerosing cholangitis","volume":"18","author":"J E Eaton","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"04","key":"ref46","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1002\/jmri.70266","article-title":"The utility of elastography in discriminating stages of liver fibrosis and risk stratification in patients with primary sclerosing cholangitis: a systematic review","volume":"63","author":"P Hashemi","year":"2026","journal-title":"J Magn Reson Imaging"},{"issue":"01","key":"ref47","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hep.27825","article-title":"Enhanced liver fibrosis score predicts transplant-free survival in primary sclerosing cholangitis","volume":"62","author":"M Vesterhus","year":"2015","journal-title":"Hepatology"},{"issue":"06","key":"ref48","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2020.07.032","article-title":"Inter- and intra-individual variation, and limited prognostic utility, of serum alkaline phosphatase in a trial of patients with primary sclerosing cholangitis","volume":"19","author":"P J Trivedi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"31","key":"ref49","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.3748\/wjg.v18.i31.4150","article-title":"Adjusting CA19-9 values to predict malignancy in obstructive jaundice: influence of bilirubin and C-reactive protein","volume":"18","author":"G La Greca","year":"2012","journal-title":"World J Gastroenterol"},{"issue":"01","key":"ref50","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5009\/gnl15568","article-title":"Cholangiocarcinoma: current knowledge and new developments","volume":"11","author":"B Blechacz","year":"2017","journal-title":"Gut Liver"},{"issue":"10","key":"ref51","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1056\/NEJM199703063361003","article-title":"Ursodiol for primary sclerosing cholangitis","volume":"336","author":"K D Lindor","year":"1997","journal-title":"N Engl J Med"},{"issue":"03","key":"ref52","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.23082","article-title":"High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis","volume":"50","author":"K D Lindor","year":"2009","journal-title":"Hepatology"},{"issue":"09","key":"ref53","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1038\/ajg.2011.156","article-title":"High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis","volume":"106","author":"J E Eaton","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/hep.23631","article-title":"Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: relation to disease progression","volume":"52","author":"E Sinakos","year":"2010","journal-title":"Hepatology"},{"issue":"05","key":"ref55","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1053\/j.gastro.2005.08.017","article-title":"High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study","volume":"129","author":"R Olsson","year":"2005","journal-title":"Gastroenterology"},{"issue":"12","key":"ref56","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1111\/liv.13110","article-title":"Alkaline phosphatase at diagnosis of primary sclerosing cholangitis and 1 year later: evaluation of prognostic value","volume":"36","author":"E M de Vries","year":"2016","journal-title":"Liver Int"},{"issue":"04","key":"ref57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.dld.2010.12.008","article-title":"Alkaline phosphatase normalization is associated with better prognosis in primary sclerosing cholangitis","volume":"43","author":"P P Stanich","year":"2011","journal-title":"Dig Liver Dis"},{"issue":"02","key":"ref58","first-page":"246","article-title":"Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis","volume":"15","author":"M Hilscher","year":"2016","journal-title":"Ann Hepatol"},{"issue":"05","key":"ref59","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00535-020-01663-1","article-title":"An update on primary sclerosing cholangitis epidemiology, outcomes and quantification of alkaline phosphatase variability in a population-based cohort","volume":"55","author":"Z Bakhshi","year":"2020","journal-title":"J Gastroenterol"},{"issue":"03","key":"ref60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/hep.27074","article-title":"Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis","volume":"60","author":"E Wunsch","year":"2014","journal-title":"Hepatology"},{"issue":"03","key":"ref61","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","author":"European Association for the Study of the Liver","year":"2022","journal-title":"J Hepatol"},{"issue":"06","key":"ref62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/hep.20943","article-title":"Novel biotransformation and physiological properties of norursodeoxycholic acid in humans","volume":"42","author":"A F Hofmann","year":"2005","journal-title":"Hepatology"},{"issue":"05","key":"ref63","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jhep.2021.06.036","article-title":"24-Norursodeoxycholic acid reshapes immunometabolism in CD8+ T cells and alleviates hepatic inflammation","volume":"75","author":"C Zhu","year":"2021","journal-title":"J Hepatol"},{"issue":"03","key":"ref64","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1159\/000454904","article-title":"Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases","volume":"35","author":"E Halilbasic","year":"2017","journal-title":"Dig Dis"},{"issue":"01","key":"ref67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","volume":"84","author":"C Levy","year":"2026","journal-title":"J Hepatol"},{"issue":"06","key":"ref69","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.clinre.2018.06.009","article-title":"Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: French-Spanish experience","volume":"42","author":"S Lemoinne","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"04","key":"ref70","doi-asserted-by":"crossref","first-page":"e00984","DOI":"10.1002\/prp2.984","article-title":"Fenofibrate in primary sclerosing cholangitis; a randomized, double-blind, placebo-controlled trial","volume":"10","author":"B Hatami","year":"2022","journal-title":"Pharmacol Res Perspect"},{"issue":"12","key":"ref71","doi-asserted-by":"crossref","first-page":"e162270","DOI":"10.1172\/jci.insight.162270","article-title":"CCL24 regulates biliary inflammation and fibrosis in primary sclerosing cholangitis","volume":"8","author":"R Greenman","year":"2023","journal-title":"JCI Insight"},{"issue":"09","key":"ref72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1007\/s40264-024-01436-2","article-title":"Targeting CCL24 in inflammatory and fibrotic diseases: rationale and results from three CM-101 phase 1 studies","volume":"47","author":"A Mor","year":"2024","journal-title":"Drug Saf"},{"issue":"01","key":"ref73","first-page":"100064","article-title":"A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage","volume":"2","author":"M Segal-Salto","year":"2020","journal-title":"JHEP Rep Innov Hepatol"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003853","article-title":"Nebokitug, an anti-chemokine (C-C motif) ligand 24 monoclonal antibody, in patients with primary sclerosing cholangitis: a phase 2 study","author":"C L Bowlus","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"04","key":"ref76","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1055\/s-0039-1688501","article-title":"Effects of antibiotic therapy in primary sclerosing cholangitis with and without inflammatory bowel disease: a systematic review and meta-analysis","volume":"39","author":"A Shah","year":"2019","journal-title":"Semin Liver Dis"},{"issue":"01","key":"ref77","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/MPG.0b013e31816fee95","article-title":"Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic","volume":"47","author":"Y K Davies","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"08","key":"ref78","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1080\/00365521.2020.1787501","article-title":"Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitis","volume":"55","author":"A H Ali","year":"2020","journal-title":"Scand J Gastroenterol"},{"issue":"06","key":"ref79","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/apt.12232","article-title":"Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study","volume":"37","author":"J H Tabibian","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"issue":"03","key":"ref80","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/hep.31560","article-title":"Oral vancomycin, ursodeoxycholic acid, or no therapy for pediatric primary sclerosing cholangitis: a matched analysis","volume":"73","author":"M R Deneau","year":"2021","journal-title":"Hepatology"},{"issue":"10","key":"ref81","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/apt.17936","article-title":"Oral vancomycin is associated with improved inflammatory bowel disease clinical outcomes in primary sclerosing cholangitis-associated inflammatory bowel disease (PSC-IBD): a matched analysis from the Paediatric PSC Consortium","volume":"59","author":"A Ricciuto","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"01","key":"ref82","doi-asserted-by":"crossref","first-page":"e106630","DOI":"10.1136\/bmjopen-2025-106630","article-title":"Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with\/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial","volume":"16","author":"L Cristoferi","year":"2026","journal-title":"BMJ Open"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000004135","article-title":"Oral vancomycin is not associated with meaningful changes in liver-related endpoints among adults with primary sclerosing cholangitis: A randomized, placebo-controlled trial","author":"J E Eaton","year":"2026","journal-title":"Am J Gastroenterol"},{"issue":"01","key":"ref84","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3390\/foods13010096","article-title":"Leuconostoc citreum: a promising sourdough fermenting starter for low-sugar-content baked goods","volume":"13","author":"M F Ro\u0219ca","year":"2023","journal-title":"Foods"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2026.101789","article-title":"Microbial monotherapy with Leuconostoc sp. LB-P8 improves inflammation and fibrosis in mouse primary sclerosing cholangitis by inhibiting TGF\u03b2\/SMAD signaling","volume":"101789","author":"K Park","year":"2026","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"ref88","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1159\/000440829","article-title":"Pathogenesis and management of pruritus in PBC and PSC","volume":"33","author":"A E Kremer","year":"2015","journal-title":"Dig Dis"},{"issue":"01","key":"ref89","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"J Xu","year":"2023","journal-title":"Hepatology"},{"issue":"01","key":"ref90","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"A E Kremer","year":"2024","journal-title":"Hepatology"},{"issue":"03","key":"ref91","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"E de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"01","key":"ref92","doi-asserted-by":"crossref","first-page":"102132","DOI":"10.1016\/j.aohep.2025.102132","article-title":"Fenofibrate in managing cholestatic pruritus in paediatric patients","volume":"31","author":"J Quintero-Bernabeu","year":"2026","journal-title":"Ann Hepatol"},{"issue":"07","key":"ref93","doi-asserted-by":"crossref","first-page":"7697","DOI":"10.21037\/apm-21-1304","article-title":"Fibrates for the treatment of pruritus in primary biliary cholangitis: a systematic review and meta-analysis","volume":"10","author":"N Shen","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"03","key":"ref95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/mp060022d","article-title":"Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target","volume":"3","author":"A Balakrishnan","year":"2006","journal-title":"Mol Pharm"},{"issue":"03","key":"ref96","doi-asserted-by":"crossref","first-page":"e70524","DOI":"10.1111\/liv.70524","article-title":"Ileal bile acid transporter inhibitors in cholestasis: potential for more than just paediatrics?","volume":"46","author":"M Krishna","year":"2026","journal-title":"Liver Int"},{"issue":"01","key":"ref97","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"G M Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"06","key":"ref98","doi-asserted-by":"crossref","first-page":"e0153","DOI":"10.1097\/HC9.0000000000000153","article-title":"Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: open-label pilot study","volume":"7","author":"C L Bowlus","year":"2023","journal-title":"Hepatol Commun"},{"issue":"01","key":"ref102","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","article-title":"Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis","volume":"8","author":"S Al-Dury","year":"2018","journal-title":"Sci Rep"},{"issue":"08","key":"ref103","doi-asserted-by":"crossref","first-page":"e70216","DOI":"10.1111\/liv.70216","article-title":"Odevixibat for episodic intrahepatic cholestasis due to biallelic mutations in ATP8B1: a case series","volume":"45","author":"A Di Giorgio","year":"2025","journal-title":"Liver Int"},{"issue":"07","key":"ref104","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1001\/jamadermatol.2025.1471","article-title":"Nemolizumab for cholestatic pruritus in a patient with liver transplant and primary sclerosing cholangitis","volume":"161","author":"G Soto-Canetti","year":"2025","journal-title":"JAMA Dermatol"},{"issue":"03","key":"ref105","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jaad.2025.11.051","article-title":"Efficacy of dupilumab for the treatment of moderate-to-severe chronic hepatic pruritus: an open-label, single-arm, exploratory study","volume":"94","author":"L A Evans","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-026-02195-0","article-title":"Development of a clinically viable MRGPRX4 inverse agonist for cholestatic itch treatment","author":"J Yang","year":"2026","journal-title":"Nat Chem Biol"},{"issue":"06","key":"ref107","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/bjd.17933","article-title":"Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy","volume":"181","author":"A B Hussain","year":"2019","journal-title":"Br J Dermatol"},{"issue":"05","key":"ref108","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1159\/000360518","article-title":"Advances in pathogenesis and management of pruritus in cholestasis","volume":"32","author":"A E Kremer","year":"2014","journal-title":"Dig Dis"},{"issue":"03","key":"ref109","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jhep.2012.04.023","article-title":"Cholestasis-induced pruritus treated with ultraviolet B phototherapy: an observational case series study","volume":"57","author":"S Decock","year":"2012","journal-title":"J Hepatol"},{"issue":"05","key":"ref110","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/liv.13281","article-title":"Plasmapheresis exerts a long-lasting antipruritic effect in severe cholestatic itch","volume":"37","author":"M Krawczyk","year":"2017","journal-title":"Liver Int"},{"issue":"06","key":"ref111","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2036.2012.04994.x","article-title":"\u2018Out-patient\u2019 albumin dialysis for cholestatic patients with intractable pruritus","volume":"35","author":"P Leckie","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"02","key":"ref112","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jhep.2010.02.031","article-title":"Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers","volume":"53","author":"A Par\u00e9s","year":"2010","journal-title":"J Hepatol"},{"issue":"01","key":"ref113","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cld.2015.08.007","article-title":"Understanding and treating fatigue in primary biliary cirrhosis and primary sclerosing cholangitis","volume":"20","author":"L Jopson","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"01","key":"ref114","first-page":"1","article-title":"Pathogenesis and management of fatigue in primary biliary cholangitis","volume":"10","author":"D Shamshtein","year":"2022","journal-title":"Fatigue"},{"issue":"02","key":"ref117","doi-asserted-by":"crossref","first-page":"e167","DOI":"10.1097\/MJT.0000000000000387","article-title":"A randomized, placebo-controlled clinical trial of efficacy and safety: modafinil in the treatment of fatigue in patients with primary biliary cirrhosis","volume":"24","author":"M G Silveira","year":"2017","journal-title":"Am J Ther"},{"issue":"05","key":"ref118","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/hep.30099","article-title":"Rituximab is ineffective for treatment of fatigue in primary biliary cholangitis: a phase 2 randomized controlled trial","volume":"70","author":"A Khanna","year":"2019","journal-title":"Hepatology"},{"issue":"11","key":"ref119","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s10620-006-9397-5","article-title":"Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double-blind controlled trial","volume":"51","author":"J A Talwalkar","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"01","key":"ref120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2036.2003.01398.x","article-title":"Oral antioxidant supplementation for fatigue associated with primary biliary cirrhosis: results of a multicentre, randomized, placebo-controlled, cross-over trial","volume":"17","author":"M I Prince","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"ref121","first-page":"101210","article-title":"A home-based exercise programme attenuates fatigue in primary biliary cholangitis: results from the EXCITED clinical trial","volume":"6","author":"A Freer","year":"2024","journal-title":"JHEP Rep Innov Hepatol"},{"issue":"03","key":"ref123","doi-asserted-by":"crossref","first-page":"e0057","DOI":"10.1097\/HC9.0000000000000057","article-title":"Impact of setanaxib on quality of life outcomes in primary biliary cholangitis in a phase 2 randomized controlled trial","volume":"7","author":"D Jones","year":"2023","journal-title":"Hepatol Commun"},{"issue":"04","key":"ref124","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1002\/hep.23804","article-title":"Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis","volume":"52","author":"S De Minicis","year":"2010","journal-title":"Hepatology"},{"issue":"09","key":"ref125","doi-asserted-by":"crossref","first-page":"e45285","DOI":"10.1371\/journal.pone.0045285","article-title":"NADPH oxidase NOX4 mediates stellate cell activation and hepatocyte cell death during liver fibrosis development","volume":"7","author":"P Sancho","year":"2012","journal-title":"PLoS One"},{"issue":"03","key":"ref126","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jhep.2019.04.012","article-title":"Activated hepatic stellate cells and portal fibroblasts contribute to cholestatic liver fibrosis in MDR2 knockout mice","volume":"71","author":"T Nishio","year":"2019","journal-title":"J Hepatol"},{"issue":"04","key":"ref127","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/jcmm.17649","article-title":"Pre-clinical evidence of a dual NADPH oxidase 1\/4 inhibitor (setanaxib) in liver, kidney and lung fibrosis","volume":"27","author":"V J Thannickal","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"07","key":"ref128","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/liv.15596","article-title":"Setanaxib, a first-in-class selective NADPH oxidase 1\/4 inhibitor for primary biliary cholangitis: a randomized, placebo-controlled, phase 2 trial","volume":"43","author":"P Invernizzi","year":"2023","journal-title":"Liver Int"},{"issue":"03","key":"ref129","first-page":"736","article-title":"Guidelines on the diagnosis and management of primary biliary cholangitis (2021)","volume":"11","author":"H You","year":"2023","journal-title":"J Clin Transl Hepatol"}],"container-title":["Seminars in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2952-2261.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:38:48Z","timestamp":1790894328000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2952-2261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":110,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,10,1]]},"published-print":{"date-parts":[[2026,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2952-2261","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0272-8087","1098-8971"],"issn-type":[{"value":"0272-8087","type":"print"},{"value":"1098-8971","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]}}}